PubRank

Jill E Slansky

Author PubWeight™ 22.53‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012 1.53
2 Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest 2006 1.40
3 Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands. Immunol Rev 2006 1.33
4 Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res 2006 1.25
5 Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003 1.25
6 Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol 2003 1.18
7 Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer 2010 1.13
8 Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2002 1.10
9 Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res 2007 1.08
10 Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol 2007 1.08
11 A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol 2006 1.06
12 Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol 2008 0.99
13 Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A 2010 0.96
14 Improving T cell responses to modified peptides in tumor vaccines. Immunol Res 2013 0.90
15 TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother 2012 0.89
16 Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. Cancer Res 2012 0.84
17 Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem 2013 0.81
18 Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res 2013 0.80
19 Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. J Immunol 2011 0.78
20 Vaccination of mice with baculovirus-infected insect cells expressing antigenic proteins. Curr Protoc Immunol 2009 0.77
21 Mimotope vaccine efficacy gets a "boost" from native tumor antigens. Oncoimmunology 2013 0.75